Pay in 4 interest-free payments of $6.74 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
[DOI] [PMC free article] [PubMed] [Google Scholar] Arul, D
This lab-verified approach helps reduce audit risk and supports long-term compliance with evolving pharmaceutical guidelines
Composition GHK-Cu: 50 mg KPV: 10 mg BPC-157: 10 mg TB-500 (Thymosin Beta 4): 10 mg Appearance: lyophilized powder in a sealed research vial Research Focus (non-clinical) Combined evaluation of copper peptide, KPV tripeptide, BPC-157, and TB-500 in in-vitro or ex-vivo assay systems Assay development, including chromatographic separation of four co-formulated peptides Stability characterization of a four-analyte lyophilized blend under laboratory storage conditions Method documentation for HPLC/LC-MS identity and purity assessments Documentation Lot-specific COA available Batch and lot traceability Important Notice For research use only Not for human consumption Not intended to diagnose, treat, cure, or prevent any disease Quality & Manufacturing Lot-specific COA Lyophilized for transit stability
Current consensus definition: prevalence, etiology, and consequences
This review is a promising approach with the objective to articulate the idea of revolutionizing wound care with different peptide combinations that can be topically applied
US$ 21.53
US$ 22.76
US$ 24.86
US$ 23.93
US$ 28.77
US$ 28.53
US$ 28.60
US$ 25.79
US$ 28.05
US$ 26.57
US$ 25.83
US$ 29.51
US$ 29.47
US$ 29.90
